All In Biotech

Drug Trial Radar · NCT03515044

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

Last checked: Nov 20, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

71

Actual

Start

Sep 13, 2018

Primary completion

Mar 12, 2020

Study completion Mar 12, 2020

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
May 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).

Conditions

  • Overt Hepatic Encephalopathy

Interventions

  • 40 mg Rifaximin SSD once dailyDrug

    SSD once daily (QD)

  • 40 mg Rifaximin SSD twice dailyDrug

    SSD twice daily (BID)

  • 80 mg Rifaximin SSD once dailyDrug

    SSD once daily (QD)

  • 80 mg Rifaximin SSD twice dailyDrug

    SSD twice daily (BID)

  • PlaceboDrug

    Administered twice daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Overt Hepatic Encephalopathy (OHE) Resolution Determined Using the Hepatic Encephalopathy Grading Instrument (HEGI), Defined as HEGI Score < 2Time frame: 14 days

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Health Site 18

    Corona del Mar, California

  • Bausch Health Site 15

    Los Angeles, California

  • Bausch Health Site 19

    Los Angeles, California

  • Bausch Health Site 04

    San Francisco, California

  • Bausch Health Site 13

    Bristol, Connecticut

  • Bausch Health Site 08

    Miami, Florida

  • Bausch Health Site 05

    Chicago, Illinois

  • Bausch Health Site 33

    Iowa City, Iowa

  • Bausch Health Site 03

    Boston, Massachusetts

  • Bausch Health Site 07

    Detroit, Michigan

  • Bausch Health 01

    Detroit, Michigan

  • Bausch Health Site 25

    Tupelo, Mississippi

  • Bausch Health Site 24

    St Louis, Missouri

  • Bausch Health Site 27

    Newark, New Jersey

  • Bausch Health Site 36

    Brooklyn, New York

  • Bausch Health Site 09

    New York, New York

  • Bausch Health Site 28

    New York, New York

  • Bausch Health Site 17

    Cincinnati, Ohio

  • Bausch Health Site 23

    Columbus, Ohio

  • Bausch Health Site 11

    Philadelphia, Pennsylvania

  • Bausch Health Site 26

    Philadelphia, Pennsylvania

  • Bausch Health Site 10

    Philadelphia, Pennsylvania

  • Bausch Health Site 12

    Pittsburgh, Pennsylvania

  • Bausch Health Site 16

    Charleston, South Carolina

  • Bausch Health Site 22

    Dallas, Texas

  • Bausch Health Site 35

    Dallas, Texas

  • Bausch Health Site 31

    Dallas, Texas

  • Bausch Health Site 02

    Houston, Texas

  • Bausch Health Site 37

    Houston, Texas

  • Bausch Health Site 30

    Richmond, Virginia

  • Bausch Health Site 06

    Richmond, Virginia

  • Bausch Health Site 21

    Seattle, Washington

  • Bausch Health Site 14

    Seattle, Washington

  • Bausch Health Site 20

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.